• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Debrisoquine hydroxylation in a Polish population.

作者信息

Kunicki P K, Sitkiewicz D, Pawlik A, Bielicka-Sulzyc V, Borowiecka E, Gawrońska-Szklarz B, Sterna R, Matsumoto H, Radziwoń-Zaleska M

机构信息

Department of Clinical Biochemistry, National Institute of Cardiology, Warszawa, Poland.

出版信息

Eur J Clin Pharmacol. 1995;47(6):503-5. doi: 10.1007/BF00193702.

DOI:10.1007/BF00193702
PMID:7768252
Abstract

The genetic polymorphism of drug oxidation mediated by cytochrome P450IID6 (CYP2D6) was determined in 154 Polish volunteers using debrisoquine as the test substance. The results showed a bimodal distribution of the debrisoquine metabolic ratio (MR). Nine persons (5.8%) with MR > 12.6 were classified as poor metabolisers (gene frequency 0.242), which is in substantial agreement with the data reported for other Caucasian populations.

摘要

相似文献

1
Debrisoquine hydroxylation in a Polish population.
Eur J Clin Pharmacol. 1995;47(6):503-5. doi: 10.1007/BF00193702.
2
Debrisoquine and S-mephenytoin hydroxylation polymorphisms in a Russian population living in Estonia.居住在爱沙尼亚的俄罗斯人群中的异喹胍和S-美芬妥因羟基化多态性
Eur J Clin Pharmacol. 1997;53(3-4):257-60. doi: 10.1007/s002280050372.
3
Genetic polymorphism of debrisoquine (CYP2D6) and proguanil (CYP2C19) in South Pacific Polynesian populations.南太平洋波利尼西亚人群中异喹胍（CYP2D6）和氯胍（CYP2C19）的基因多态性。
Eur J Clin Pharmacol. 1998 Jul;54(5):431-5. doi: 10.1007/s002280050488.
4
Debrisoquine 4-hydroxylation (CYP2D6) polymorphism in Jordanians.
Pharmacogenetics. 1994 Jun;4(3):159-61. doi: 10.1097/00008571-199406000-00007.
5
Lack of congruence of S-carboxymethyl-L-cysteine sulphoxidation and debrisoquine 4-hydroxylation in a Caucasian population.
Xenobiotica. 1985 May;15(5):445-50. doi: 10.3109/00498258509045015.
6
Reproducibility over time of mephenytoin and debrisoquine hydroxylation phenotypes.美芬妥英和异喹胍羟基化表型随时间的再现性。
Pharmacol Toxicol. 1993 Jul;73(1):46-8. doi: 10.1111/j.1600-0773.1993.tb01956.x.
7
Ultrarapid hydroxylation of debrisoquine in a Swedish population. Analysis of the molecular genetic basis.瑞典人群中异喹胍的超快速羟化作用。分子遗传基础分析。
J Pharmacol Exp Ther. 1995 Jul;274(1):516-20.
8
Genetic and metabolic criteria for the assignment of debrisoquine 4-hydroxylation (cytochrome P4502D6) phenotypes.用于确定异喹胍4-羟化（细胞色素P4502D6）表型的遗传和代谢标准。
Pharmacogenetics. 1991 Oct;1(1):33-41. doi: 10.1097/00008571-199110000-00006.
9
Debrisoquine hydroxylation genotype in familial forms of idiopathic Parkinson's disease.家族性特发性帕金森病中的异喹胍羟基化基因型
Adv Neurol. 1996;69:97-100.
10
Quinidine inhibition of debrisoquine S(+)-4- and 7-hydroxylations in Chinese of different CYP2D6 genotypes.奎尼丁对不同CYP2D6基因型中国人中去甲丙咪嗪S(+)-4-和7-羟化作用的抑制
Pharmacogenetics. 1993 Apr;3(2):94-100. doi: 10.1097/00008571-199304000-00005.

本文引用的文献

1
Polymorphism of debrisoquine and mephenytoin hydroxylation among Estonians.爱沙尼亚人对异喹胍和苯妥英羟化作用的多态性
Pharmacol Toxicol. 1993 Feb;72(2):113-5. doi: 10.1111/j.1600-0773.1993.tb00300.x.
2
Metabolic polymorphisms.代谢多态性
Pharmacol Ther. 1993 Feb-Mar;57(2-3):129-60. doi: 10.1016/0163-7258(93)90053-g.
3
Debrisoquine oxidation polymorphism: phenotypic consequences of a 3-base-pair deletion in exon 5 of the CYP2D6 gene.异喹胍氧化多态性：CYP2D6基因第5外显子3个碱基对缺失的表型后果。
Pharmacogenetics. 1993 Jun;3(3):123-30.
4
Genetically determined sparteine oxidation polymorphism in a Polish population.
Eur J Clin Pharmacol. 1994;46(5):481-3. doi: 10.1007/BF00191917.
5
Inherited amplification of an active gene in the cytochrome P450 CYP2D locus as a cause of ultrarapid metabolism of debrisoquine.细胞色素P450 CYP2D基因座中一个活性基因的遗传性扩增是导致异喹胍超快代谢的原因。
Proc Natl Acad Sci U S A. 1993 Dec 15;90(24):11825-9. doi: 10.1073/pnas.90.24.11825.
6
DNA haplotype dependency of debrisoquine 4-hydroxylase (CYP2D6) expression among extensive metabolisers.
Hum Genet. 1993 Oct;92(4):367-72. doi: 10.1007/BF01247337.
7
A family and population study of the genetic polymorphism of debrisoquine oxidation in a white British population.对英国白人人群中异喹胍氧化遗传多态性的家系及群体研究。
J Med Genet. 1980 Apr;17(2):102-5. doi: 10.1136/jmg.17.2.102.
8
Determination of debrisoquine and its 4-hydroxy metabolite in urine by high-performance liquid chromatography.高效液相色谱法测定尿中异喹胍及其4-羟基代谢物
J Chromatogr. 1986 Jan 10;374(1):204-8. doi: 10.1016/s0378-4347(00)83273-9.
9
The metabolism of debrisoquine in man: (1) regioselectivity of hydroxylation and (2) aberrant oxidative metabolism in two sibling patients with carbimazole-induced agranulocytosis.人体内异喹胍的代谢：（1）羟基化的区域选择性以及（2）两名患有卡比马唑诱导的粒细胞缺乏症的同胞患者的异常氧化代谢。
Xenobiotica. 1986 May;16(5):503-9. doi: 10.3109/00498258609050255.
10
Comparison of gas chromatographic and high-performance liquid chromatographic assays for the determination of debrisoquine and its 4-hydroxy metabolite in human fluids.
J Chromatogr. 1988 Mar 18;425(2):311-21. doi: 10.1016/0378-4347(88)80035-5.